nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—ORM1—saliva—conduct disorder	0.191	0.206	CbGeAlD
Erlotinib—HIPK4—brain—conduct disorder	0.0625	0.0675	CbGeAlD
Erlotinib—LTK—brain—conduct disorder	0.0618	0.0668	CbGeAlD
Erlotinib—AURKC—brain—conduct disorder	0.0534	0.0576	CbGeAlD
Erlotinib—EPHA6—brain—conduct disorder	0.0494	0.0534	CbGeAlD
Erlotinib—JAK3—brain—conduct disorder	0.0494	0.0534	CbGeAlD
Erlotinib—TNK1—brain—conduct disorder	0.0454	0.049	CbGeAlD
Erlotinib—MAP3K19—brain—conduct disorder	0.0449	0.0485	CbGeAlD
Erlotinib—ABL2—brain—conduct disorder	0.0372	0.0402	CbGeAlD
Erlotinib—EGFR—brain—conduct disorder	0.0363	0.0392	CbGeAlD
Erlotinib—PIP4K2C—brain—conduct disorder	0.0352	0.038	CbGeAlD
Erlotinib—ULK3—brain—conduct disorder	0.0336	0.0363	CbGeAlD
Erlotinib—MKNK1—brain—conduct disorder	0.0316	0.0342	CbGeAlD
Erlotinib—SLK—brain—conduct disorder	0.03	0.0324	CbGeAlD
Erlotinib—STK10—brain—conduct disorder	0.0261	0.0281	CbGeAlD
Erlotinib—MAP2K5—brain—conduct disorder	0.0233	0.0251	CbGeAlD
Erlotinib—SLCO2B1—brain—conduct disorder	0.0181	0.0196	CbGeAlD
Erlotinib—ABL1—brain—conduct disorder	0.018	0.0194	CbGeAlD
Erlotinib—ALB—brain—conduct disorder	0.0166	0.0179	CbGeAlD
Erlotinib—CYP1B1—brain—conduct disorder	0.0152	0.0164	CbGeAlD
Erlotinib—CYP2C8—brain—conduct disorder	0.0116	0.0126	CbGeAlD
Erlotinib—ABCG2—brain—conduct disorder	0.0113	0.0122	CbGeAlD
Erlotinib—CYP1A1—brain—conduct disorder	0.0107	0.0116	CbGeAlD
Erlotinib—CYP2D6—brain—conduct disorder	0.00776	0.00838	CbGeAlD
Erlotinib—PIP4K2C—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.00773	0.104	CbGpPWpGaD
Erlotinib—ABCB1—brain—conduct disorder	0.00558	0.00603	CbGeAlD
Erlotinib—UGT1A1—Estrogen metabolism—COMT—conduct disorder	0.00304	0.0411	CbGpPWpGaD
Erlotinib—CYP1B1—Estrogen metabolism—COMT—conduct disorder	0.00284	0.0383	CbGpPWpGaD
Erlotinib—ABL1—Regulation of actin dynamics for phagocytic cup formation—WASF1—conduct disorder	0.00228	0.0309	CbGpPWpGaD
Erlotinib—CYP1B1—Melatonin metabolism and effects—MAOA—conduct disorder	0.00192	0.026	CbGpPWpGaD
Erlotinib—CYP1A2—Methylation—COMT—conduct disorder	0.00178	0.0241	CbGpPWpGaD
Erlotinib—CYP1A1—Estrogen metabolism—COMT—conduct disorder	0.00175	0.0236	CbGpPWpGaD
Erlotinib—ABL1—Fcgamma receptor (FCGR) dependent phagocytosis—WASF1—conduct disorder	0.00172	0.0233	CbGpPWpGaD
Erlotinib—CYP1A1—Melatonin metabolism and effects—MAOA—conduct disorder	0.00118	0.016	CbGpPWpGaD
Erlotinib—CYP1A1—Oxidative Stress—MAOA—conduct disorder	0.00115	0.0156	CbGpPWpGaD
Erlotinib—JAK3—IL-4 Signaling Pathway—EP300—conduct disorder	0.00113	0.0152	CbGpPWpGaD
Erlotinib—CYP1A2—Estrogen metabolism—COMT—conduct disorder	0.00111	0.0151	CbGpPWpGaD
Erlotinib—EGFR—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.000905	0.0122	CbGpPWpGaD
Erlotinib—CYP2D6—Melatonin metabolism and effects—MAOA—conduct disorder	0.000892	0.012	CbGpPWpGaD
Erlotinib—CYP1B1—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.000872	0.0118	CbGpPWpGaD
Erlotinib—CYP3A4—Estrogen metabolism—COMT—conduct disorder	0.00086	0.0116	CbGpPWpGaD
Erlotinib—UGT1A1—Phase II conjugation—COMT—conduct disorder	0.000855	0.0115	CbGpPWpGaD
Erlotinib—CYP1A2—Melatonin metabolism and effects—MAOA—conduct disorder	0.000755	0.0102	CbGpPWpGaD
Erlotinib—UGT1A1—NRF2 pathway—SLC6A4—conduct disorder	0.000752	0.0102	CbGpPWpGaD
Erlotinib—ABCG2—HIF-2-alpha transcription factor network—EP300—conduct disorder	0.000665	0.00899	CbGpPWpGaD
Erlotinib—SLCO2B1—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.000662	0.00895	CbGpPWpGaD
Erlotinib—JAK3—Immune System—MB21D1—conduct disorder	0.00066	0.00892	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways in Glioblastoma—EP300—conduct disorder	0.000657	0.00888	CbGpPWpGaD
Erlotinib—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EP300—conduct disorder	0.000616	0.00832	CbGpPWpGaD
Erlotinib—JAK3—GPCR downstream signaling—CGA—conduct disorder	0.000613	0.00829	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—MB21D1—conduct disorder	0.00058	0.00784	CbGpPWpGaD
Erlotinib—ABL1—Validated transcriptional targets of TAp63 isoforms—EP300—conduct disorder	0.000576	0.00779	CbGpPWpGaD
Erlotinib—CYP1B1—Aryl Hydrocarbon Receptor—EP300—conduct disorder	0.000574	0.00776	CbGpPWpGaD
Erlotinib—CYP1B1—Aryl Hydrocarbon Receptor Pathway—EP300—conduct disorder	0.000574	0.00776	CbGpPWpGaD
Erlotinib—CYP3A5—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.000568	0.00768	CbGpPWpGaD
Erlotinib—NR1I2—Gene Expression—POLR3A—conduct disorder	0.000567	0.00766	CbGpPWpGaD
Erlotinib—EGFR—Aryl Hydrocarbon Receptor Pathway—EP300—conduct disorder	0.00056	0.00756	CbGpPWpGaD
Erlotinib—EGFR—Aryl Hydrocarbon Receptor—EP300—conduct disorder	0.00056	0.00756	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—CGA—conduct disorder	0.000557	0.00753	CbGpPWpGaD
Erlotinib—CYP1A1—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.000537	0.00725	CbGpPWpGaD
Erlotinib—ABL1—p53 pathway—EP300—conduct disorder	0.000537	0.00725	CbGpPWpGaD
Erlotinib—UGT1A1—Biological oxidations—COMT—conduct disorder	0.0005	0.00676	CbGpPWpGaD
Erlotinib—UGT1A1—Biological oxidations—MAOA—conduct disorder	0.000496	0.00671	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—MB21D1—conduct disorder	0.000496	0.0067	CbGpPWpGaD
Erlotinib—UGT1A1—Metapathway biotransformation—COMT—conduct disorder	0.000493	0.00666	CbGpPWpGaD
Erlotinib—CYP2C8—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.000492	0.00665	CbGpPWpGaD
Erlotinib—ABL1—Regulation of retinoblastoma protein—EP300—conduct disorder	0.000491	0.00663	CbGpPWpGaD
Erlotinib—JAK3—Immune System—POLR3A—conduct disorder	0.000485	0.00655	CbGpPWpGaD
Erlotinib—CYP1B1—Biological oxidations—COMT—conduct disorder	0.000466	0.0063	CbGpPWpGaD
Erlotinib—CYP1B1—Biological oxidations—MAOA—conduct disorder	0.000463	0.00626	CbGpPWpGaD
Erlotinib—CYP1B1—Metapathway biotransformation—COMT—conduct disorder	0.00046	0.00621	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—CGA—conduct disorder	0.000436	0.0059	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—POLR3A—conduct disorder	0.000426	0.00576	CbGpPWpGaD
Erlotinib—ABL1—p73 transcription factor network—EP300—conduct disorder	0.000425	0.00574	CbGpPWpGaD
Erlotinib—JAK3—Immune System—WASF1—conduct disorder	0.000408	0.00551	CbGpPWpGaD
Erlotinib—CYP2D6—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.000404	0.00546	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.000397	0.00536	CbGpPWpGaD
Erlotinib—ABCG2—HIF-1-alpha transcription factor network—EP300—conduct disorder	0.000391	0.00529	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—POLR3A—conduct disorder	0.000364	0.00492	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—WASF1—conduct disorder	0.000359	0.00484	CbGpPWpGaD
Erlotinib—CYP1A1—Aryl Hydrocarbon Receptor—EP300—conduct disorder	0.000354	0.00478	CbGpPWpGaD
Erlotinib—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EP300—conduct disorder	0.000354	0.00478	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways in Glioblastoma—EP300—conduct disorder	0.000352	0.00476	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—WASF1—conduct disorder	0.00035	0.00473	CbGpPWpGaD
Erlotinib—ABL1—Cell Cycle—EP300—conduct disorder	0.000346	0.00468	CbGpPWpGaD
Erlotinib—JAK3—GPCR downstream signaling—DRD4—conduct disorder	0.000344	0.00464	CbGpPWpGaD
Erlotinib—CYP1A2—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.000342	0.00463	CbGpPWpGaD
Erlotinib—ABL1—Immune System—MB21D1—conduct disorder	0.000338	0.00457	CbGpPWpGaD
Erlotinib—EGFR—Androgen receptor signaling pathway—EP300—conduct disorder	0.00033	0.00446	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CGA—conduct disorder	0.000329	0.00445	CbGpPWpGaD
Erlotinib—ABCG2—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.000322	0.00435	CbGpPWpGaD
Erlotinib—CYP1A2—Phase II conjugation—COMT—conduct disorder	0.000313	0.00423	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—DRD4—conduct disorder	0.000312	0.00422	CbGpPWpGaD
Erlotinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.000308	0.00416	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—WASF1—conduct disorder	0.000306	0.00414	CbGpPWpGaD
Erlotinib—CYP3A5—Biological oxidations—COMT—conduct disorder	0.000304	0.00411	CbGpPWpGaD
Erlotinib—CYP3A5—Biological oxidations—MAOA—conduct disorder	0.000302	0.00408	CbGpPWpGaD
Erlotinib—CYP3A5—Metapathway biotransformation—COMT—conduct disorder	0.0003	0.00405	CbGpPWpGaD
Erlotinib—EGFR—Immune System—MB21D1—conduct disorder	0.000289	0.0039	CbGpPWpGaD
Erlotinib—CYP1A1—Biological oxidations—COMT—conduct disorder	0.000287	0.00388	CbGpPWpGaD
Erlotinib—CYP1A1—Biological oxidations—MAOA—conduct disorder	0.000285	0.00385	CbGpPWpGaD
Erlotinib—CYP1A1—Metapathway biotransformation—COMT—conduct disorder	0.000283	0.00383	CbGpPWpGaD
Erlotinib—ABL2—Developmental Biology—EP300—conduct disorder	0.000278	0.00375	CbGpPWpGaD
Erlotinib—ABL1—Factors involved in megakaryocyte development and platelet production—EP300—conduct disorder	0.000275	0.00372	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CGA—conduct disorder	0.000268	0.00362	CbGpPWpGaD
Erlotinib—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.000264	0.00357	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—WASF1—conduct disorder	0.000264	0.00356	CbGpPWpGaD
Erlotinib—CYP2C8—Biological oxidations—COMT—conduct disorder	0.000263	0.00356	CbGpPWpGaD
Erlotinib—CYP2C8—Biological oxidations—MAOA—conduct disorder	0.000261	0.00353	CbGpPWpGaD
Erlotinib—CYP2C8—Metapathway biotransformation—COMT—conduct disorder	0.00026	0.00351	CbGpPWpGaD
Erlotinib—ABL1—Integrated Breast Cancer Pathway—EP300—conduct disorder	0.000253	0.00342	CbGpPWpGaD
Erlotinib—ABL1—Immune System—POLR3A—conduct disorder	0.000248	0.00335	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—DRD4—conduct disorder	0.000244	0.0033	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.000244	0.0033	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—CGA—conduct disorder	0.000244	0.00329	CbGpPWpGaD
Erlotinib—EPHA6—Developmental Biology—EP300—conduct disorder	0.000234	0.00316	CbGpPWpGaD
Erlotinib—EGFR—Direct p53 effectors—EP300—conduct disorder	0.00023	0.0031	CbGpPWpGaD
Erlotinib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—conduct disorder	0.000226	0.00305	CbGpPWpGaD
Erlotinib—CYP1A2—Aryl Hydrocarbon Receptor—EP300—conduct disorder	0.000226	0.00305	CbGpPWpGaD
Erlotinib—JAK3—GPCR downstream signaling—HTR2A—conduct disorder	0.000224	0.00303	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.000224	0.00303	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.000223	0.00301	CbGpPWpGaD
Erlotinib—EGFR—Integrated Breast Cancer Pathway—EP300—conduct disorder	0.000216	0.00292	CbGpPWpGaD
Erlotinib—CYP2D6—Biological oxidations—COMT—conduct disorder	0.000216	0.00292	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—WASF1—conduct disorder	0.000215	0.00291	CbGpPWpGaD
Erlotinib—CYP2D6—Biological oxidations—MAOA—conduct disorder	0.000215	0.0029	CbGpPWpGaD
Erlotinib—CYP2D6—Metapathway biotransformation—COMT—conduct disorder	0.000213	0.00288	CbGpPWpGaD
Erlotinib—EGFR—Immune System—POLR3A—conduct disorder	0.000212	0.00286	CbGpPWpGaD
Erlotinib—ABCB1—HIF-1-alpha transcription factor network—EP300—conduct disorder	0.000212	0.00286	CbGpPWpGaD
Erlotinib—ABL1—Integrated Pancreatic Cancer Pathway—EP300—conduct disorder	0.00021	0.00283	CbGpPWpGaD
Erlotinib—ABL1—Immune System—WASF1—conduct disorder	0.000209	0.00282	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—HTR2A—conduct disorder	0.000204	0.00275	CbGpPWpGaD
Erlotinib—ALB—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.000199	0.00268	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—CGA—conduct disorder	0.000189	0.00256	CbGpPWpGaD
Erlotinib—JAK3—Hemostasis—EP300—conduct disorder	0.000188	0.00254	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—DRD4—conduct disorder	0.000184	0.00249	CbGpPWpGaD
Erlotinib—CYP1A2—Biological oxidations—COMT—conduct disorder	0.000183	0.00247	CbGpPWpGaD
Erlotinib—CYP1A2—Biological oxidations—MAOA—conduct disorder	0.000182	0.00246	CbGpPWpGaD
Erlotinib—CYP1A2—Metapathway biotransformation—COMT—conduct disorder	0.000181	0.00244	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—EP300—conduct disorder	0.000179	0.00242	CbGpPWpGaD
Erlotinib—EGFR—Immune System—WASF1—conduct disorder	0.000178	0.00241	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—CGA—conduct disorder	0.000177	0.00239	CbGpPWpGaD
Erlotinib—CYP1A1—PPARA activates gene expression—EP300—conduct disorder	0.000176	0.00238	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.000174	0.00235	CbGpPWpGaD
Erlotinib—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—conduct disorder	0.000172	0.00233	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—CGA—conduct disorder	0.000161	0.00217	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—HTR2A—conduct disorder	0.000159	0.00215	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.000156	0.0021	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—DRD4—conduct disorder	0.00015	0.00203	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CGA—conduct disorder	0.000144	0.00195	CbGpPWpGaD
Erlotinib—CYP3A4—Biological oxidations—COMT—conduct disorder	0.000141	0.00191	CbGpPWpGaD
Erlotinib—CYP3A4—Biological oxidations—MAOA—conduct disorder	0.00014	0.0019	CbGpPWpGaD
Erlotinib—CYP3A4—Metapathway biotransformation—COMT—conduct disorder	0.000139	0.00188	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—DRD4—conduct disorder	0.000136	0.00184	CbGpPWpGaD
Erlotinib—MKNK1—Disease—EP300—conduct disorder	0.000121	0.00163	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—HTR2A—conduct disorder	0.00012	0.00162	CbGpPWpGaD
Erlotinib—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—conduct disorder	0.000119	0.0016	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—WASF1—conduct disorder	0.000115	0.00156	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—CGA—conduct disorder	0.000115	0.00156	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—CGA—conduct disorder	0.000109	0.00147	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CGA—conduct disorder	9.97e-05	0.00135	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CGA—conduct disorder	9.92e-05	0.00134	CbGpPWpGaD
Erlotinib—JAK3—Immune System—EP300—conduct disorder	9.85e-05	0.00133	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—EP300—conduct disorder	9.8e-05	0.00133	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—HTR2A—conduct disorder	9.8e-05	0.00132	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—EP300—conduct disorder	9.62e-05	0.0013	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—conduct disorder	9.04e-05	0.00122	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—HTR2A—conduct disorder	8.9e-05	0.0012	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CGA—conduct disorder	8.69e-05	0.00117	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—EP300—conduct disorder	8.66e-05	0.00117	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—COMT—conduct disorder	8.55e-05	0.00116	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—MAOA—conduct disorder	8.49e-05	0.00115	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—EP300—conduct disorder	8.45e-05	0.00114	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—EP300—conduct disorder	8.38e-05	0.00113	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CGA—conduct disorder	8.19e-05	0.00111	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—DRD4—conduct disorder	8.06e-05	0.00109	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—COMT—conduct disorder	7.97e-05	0.00108	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—MAOA—conduct disorder	7.92e-05	0.00107	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism of lipids and lipoproteins—EP300—conduct disorder	7.68e-05	0.00104	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—EP300—conduct disorder	7.4e-05	0.001	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—COMT—conduct disorder	7.25e-05	0.00098	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—MAOA—conduct disorder	7.2e-05	0.000973	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CGA—conduct disorder	6.94e-05	0.000937	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—EP300—conduct disorder	6.37e-05	0.000861	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CGA—conduct disorder	5.35e-05	0.000723	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—HTR2A—conduct disorder	5.26e-05	0.000711	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—COMT—conduct disorder	5.2e-05	0.000702	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—EP300—conduct disorder	5.19e-05	0.000702	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—MAOA—conduct disorder	5.16e-05	0.000697	CbGpPWpGaD
Erlotinib—ABL1—Immune System—EP300—conduct disorder	5.04e-05	0.000682	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—COMT—conduct disorder	4.91e-05	0.000664	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—MAOA—conduct disorder	4.88e-05	0.000659	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—EP300—conduct disorder	4.73e-05	0.00064	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—EP300—conduct disorder	4.73e-05	0.000639	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—COMT—conduct disorder	4.5e-05	0.000608	CbGpPWpGaD
Erlotinib—ALB—Metabolism—COMT—conduct disorder	4.48e-05	0.000605	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—MAOA—conduct disorder	4.47e-05	0.000604	CbGpPWpGaD
Erlotinib—ALB—Metabolism—MAOA—conduct disorder	4.44e-05	0.000601	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—conduct disorder	4.34e-05	0.000586	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—EP300—conduct disorder	4.31e-05	0.000583	CbGpPWpGaD
Erlotinib—EGFR—Immune System—EP300—conduct disorder	4.31e-05	0.000582	CbGpPWpGaD
Erlotinib—EGFR—Disease—EP300—conduct disorder	3.98e-05	0.000538	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—COMT—conduct disorder	3.92e-05	0.00053	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—MAOA—conduct disorder	3.89e-05	0.000526	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—COMT—conduct disorder	3.7e-05	0.000499	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—MAOA—conduct disorder	3.67e-05	0.000496	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—EP300—conduct disorder	3.67e-05	0.000495	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—EP300—conduct disorder	3.42e-05	0.000462	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—COMT—conduct disorder	3.13e-05	0.000423	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—EP300—conduct disorder	3.11e-05	0.00042	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—MAOA—conduct disorder	3.11e-05	0.00042	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—conduct disorder	3.02e-05	0.000407	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—EP300—conduct disorder	2.79e-05	0.000377	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—COMT—conduct disorder	2.42e-05	0.000327	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—MAOA—conduct disorder	2.4e-05	0.000324	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—EP300—conduct disorder	2.23e-05	0.000301	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—EP300—conduct disorder	2.11e-05	0.000285	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—EP300—conduct disorder	1.93e-05	0.000261	CbGpPWpGaD
Erlotinib—ALB—Metabolism—EP300—conduct disorder	1.92e-05	0.000259	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—EP300—conduct disorder	1.68e-05	0.000227	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—EP300—conduct disorder	1.59e-05	0.000214	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—EP300—conduct disorder	1.34e-05	0.000181	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—EP300—conduct disorder	1.04e-05	0.00014	CbGpPWpGaD
